Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (281-290 of 333) with videos related to

Pageof 34
Sort By:
Science Translational Medicine|December 3, 2020
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosisOlivier Govaere, Simon Cockell, Dina Tiniakos, et al.
The Lancet Regional Health. Europe|June 10, 2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseNicola Pugliese, Trenton M White, Paul N Brennan, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 13, 2019
GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic SteatohepatitisJan Best, Lars P Bechmann, Jan-Peter Sowa, et al.
Journal of Hepatology|April 17, 2020
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>☆</sup>Quentin M Anstee, Rebecca Darlay, Simon Cockell, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2025
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi studyJeffrey V Lazarus, Leire Agirre-Garrido, Trenton M White, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort studyKatrine P Lindvig, Katrine H Thorhauge, Johanne K Hansen, et al.
The Lancet. Gastroenterology & Hepatology|December 9, 2023
Implementation of a liver health check in people with type 2 diabetesKushala W M Abeysekera, Luca Valenti, Zobair Younossi, et al.
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.
Pageof 34

Showing results (281-290 of 333) with videos related to

Sort By:
Pageof 34
Science Translational Medicine|December 3, 2020
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosisOlivier Govaere, Simon Cockell, Dina Tiniakos, et al.
The Lancet Regional Health. Europe|June 10, 2026
Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver diseaseNicola Pugliese, Trenton M White, Paul N Brennan, et al.
The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|May 10, 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM studyQuentin M Anstee, Kathryn J Lucas, Sven Francque, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 13, 2019
GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic SteatohepatitisJan Best, Lars P Bechmann, Jan-Peter Sowa, et al.
Journal of Hepatology|April 17, 2020
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>☆</sup>Quentin M Anstee, Rebecca Darlay, Simon Cockell, et al.
The Lancet. Gastroenterology & Hepatology|December 15, 2025
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi studyJeffrey V Lazarus, Leire Agirre-Garrido, Trenton M White, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort studyKatrine P Lindvig, Katrine H Thorhauge, Johanne K Hansen, et al.
The Lancet. Gastroenterology & Hepatology|December 9, 2023
Implementation of a liver health check in people with type 2 diabetesKushala W M Abeysekera, Luca Valenti, Zobair Younossi, et al.
Journal of Hepatology|June 11, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, et al.
Pageof 34